AstraZeneca settles row over patent on cholesterol product

 
City A.M. Reporter
ASTRAZENECA has seen off a remaining threat to its top-selling cholesterol drug Crestor by settling a US legal case with generic firms Watson Laboratories, a unit of Actavis, and Egis.

The settlement follows a US appeal court ruling in December involving other firms upholding the patent on the medicine, which AstraZeneca is relying on as sales of other products tumble.

The agreement allows Watson to begin selling a generic form of Crestor on 2 May 2016, at a fee to AstraZeneca of 39 per cent of net sales, until the end of pediatric exclusivity on the drug on 8 July 2016.